Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Principal Financial Group Inc. reduced its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 95.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,807 shares of the biotechnology company’s stock after selling 393,607 shares during the quarter. Principal Financial Group Inc.’s holdings in BioCryst Pharmaceuticals were worth $134,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC lifted its holdings in BioCryst Pharmaceuticals by 44.5% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 17,344 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 5,340 shares during the last quarter. Aigen Investment Management LP increased its position in shares of BioCryst Pharmaceuticals by 75.0% in the third quarter. Aigen Investment Management LP now owns 28,661 shares of the biotechnology company’s stock worth $218,000 after purchasing an additional 12,280 shares during the period. Counterweight Ventures LLC increased its position in shares of BioCryst Pharmaceuticals by 591.7% in the third quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock worth $710,000 after purchasing an additional 79,884 shares during the period. Intech Investment Management LLC bought a new position in shares of BioCryst Pharmaceuticals in the third quarter worth $412,000. Finally, Charles Schwab Investment Management Inc. grew its position in BioCryst Pharmaceuticals by 5.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,887,994 shares of the biotechnology company’s stock valued at $14,349,000 after acquiring an additional 102,860 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Down 2.2 %

Shares of BCRX opened at $7.69 on Friday. The stock has a market cap of $1.61 billion, a P/E ratio of -12.61 and a beta of 1.85. The business’s fifty day moving average is $8.15 and its 200 day moving average is $7.87. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. The business’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.28 earnings per share. On average, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analyst Upgrades and Downgrades

BCRX has been the topic of several research reports. Evercore ISI boosted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Wedbush started coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price objective on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Finally, JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.